Pricing Log in Create free account
Friday 6 November 2026 Export MRKR’s income statement to Excel — free account

MARKER THERAPEUTICS, INC.

MRKR Healthcare Biotechnology

MARKER THERAPEUTICS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.5 million, down 46.2% from fiscal 2024.

Revenue
−51.0%
EPS
+69.0%
Free cash flow
−97.8%

Quarter to June 2026, against a year earlier

0.92 0.02 +2.22%
Market cap
$14.9M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
3/9
Altman Z
−28.68
Beneish M
−2.92
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 30.11%

Capital & Financial Ratios $m

Size
Market Cap 14.93
Revenue ttm 3.55
Net income ttm (8.71)
Free cash flow ttm (9.76)
Net debt Q (11.12)
Valuation
P/E 0.00
Forward P/E (1.65) (negative: loss-making)
Price / sales 5.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.46
Financial health
Current ratio Q 6.03 (at or above 1.5: strong)
Debt / equity Q 0.07 (at or below 0.5: strong)
Interest coverage Q (8.89)
Growth
Revenue growth Q −51.00% (below 0%: shrinking)
Operating income growth Q +48.84% (above 0%: growing)
EPS, this year +24.89% (at or above 15%: strong)
EPS, next year A −47.75% (below 0%: weak)
Revenue, next year A +19.60% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +10.26%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.9×, against a ten-year median of 3.4×; over the ten years it ranged from −6.6× in 2022 to 164× in 2021.
P/S against its own 10 years 20.46%
10-year low 10-year high
P/B against its own 10 years 23.43%
10-year low 10-year high
EV/Sales against its own 10 years 23.51%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 15 19 17 12
Receivables 1 2 1 2
Inventory — — — —
Other — — — —
17 22 19 15
2023 2024 2025 Q'26
Payables 2 2 1 1
ST’ Debt — 2 — 1
Other — — — —
3 3 2 2

Compound Annual Growth %

10y 5y 3y
Sales — 50.02% 0.31%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (9.29%) (5.02%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.25 Actual −0.09

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.69 −0.12 Beat by 0.57
Q4 FY25 −0.21 −0.04 Beat by 0.17
Q1 FY26 −0.18 −0.16 Beat by 0.02
Q2 FY26 −0.25 −0.09 Beat by 0.16
Q3 FY26 −0.12 — Reports 12 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.16) (0.09) — — —
’25 (0.40) (0.29) (0.12) (0.09) (0.79)
’24 (0.27) (0.25) (0.26) (0.42) (1.19)
’23 (0.57) 0.29 (0.34) (0.31) (0.94)
’22 (1.20) (1.10) (0.80) (0.46) (3.58)
’21 (1.60) (1.30) (1.50) (1.20) (5.50)
’20 (1.40) (1.40) (1.60) (1.80) (6.10)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 — — — — —
’25 0 1 1 1 4
’24 1 1 2 2 7
’23 1 1 0 1 3
’22 1 1 1 1 4
’21 — — — 1 1
’20 — 0 — — 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (4) — — —
’25 (5) (2) (3) (2) (12)
’24 (4) (4) 1 (5) (11)
’23 (6) (7) (1) (2) (16)
’22 (12) (1) (8) (6) (27)
’21 (8) (7) (8) (5) (27)
’20 (4) (4) (6) (6) (20)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (1) (4) — — —
’25 (5) (2) (3) (2) (12)
’24 (4) (4) 1 (5) (11)
’23 (6) (7) (1) (2) (16)
’22 (15) (3) (12) (11) (32)
’21 (10) (7) (9) (5) (30)
’20 (4) (8) (7) (10) (29)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue — 0 0 0 0 1 4 3 7 4 4 +44.8% 4 20 84 +187.1%
Gross margin, % — 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 134.12 0.0 pt
EBT (2) (11) (148) (21) (29) (42) (20) (14) (11) (12) (9) +19.5%
EBT margin, % 0.00 (5,997.92) (71,824.22) (10,050.66) (6,149.55) (3,372.71) (562.85) (424.09) (162.06) (343.38) 0.00 (343.4) pt
Net income (2) (11) (148) (21) (29) (42) (30) (8) (11) (12) (9) +19.5%
Per share, $
Per share, $ Revenue 0.00 0.19 0.11 0.05 0.10 0.16 0.42 0.38 0.73 0.23 0.00 n/m
Earnings (3.60) (11.60) (77.50) (4.70) (6.10) (5.50) (3.58) (0.94) (1.19) (0.79) (0.46) (15.5%)
Cash flow (9.45) (8.93) (7.58) (4.01) (4.26) (3.57) (3.23) (1.87) (1.21) (0.78) (0.51) (24.2%)
Capex 0.00 0.00 (0.08) (0.08) (1.97) (0.41) (0.59) 0.00 0.00 0.00 0.00 n/m
Free cash flow (9.45) (8.93) (7.66) (4.09) (6.23) (3.97) (3.82) (1.87) (1.21) (0.78) (0.51) (24.2%)
Book value 8.98 3.87 31.08 9.67 5.81 5.75 2.35 1.60 2.07 1.10 0.63 (20.8%)
Shares, m 1 1 2 5 5 8 8 9 9 15 18 +41.1%
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S — 0.00 0.00 0.00 63.80 34.16 6.58 14.53 4.24 6.43 5.01 14.4
P/B — 10.52 1.79 2.98 2.49 1.65 1.18 3.42 1.50 1.36 1.46 3.0
EV/Sales — 0.00 0.00 0.00 44.19 14.01 3.39 10.16 1.58 2.11 1.88 8.4
EV/FCF — (3.95) (3.05) (4.69) (1.61) (0.98) (0.29) (1.18) (0.45) (0.31) (0.30) (1.8)
Cash, $m
Cash, $m Operating cash flow (7) (8) (14) (18) (20) (27) (27) (16) (11) (12) (10) +7.0%
Capex — — 0 0 (9) (3) (5) — — — (12) +140.5%
Free cash flow (7) (8) (15) (19) (29) (30) (32) (16) (11) (12) (10) +7.0%
Balance, $m
Balance, $m Working capital 6 4 59 43 18 33 9 14 19 17 12 +11.7%
Net debt (8) (5) (62) (44) (21) (43) (11) (15) (17) (17) (11) +9.0%
Shareholders’ equity 6 4 59 44 27 44 20 14 19 17 12 +11.7%
Returns, %
Returns, % ROA (33.71) (167.64) (439.54) (39.50) (62.42) (73.63) (58.37) (31.96) (54.82) (59.20) (59.33) (25.5) pt
ROIC 0.00 0.00 0.00 (3,644.97) (282.93) (2,225.27) (147.32) 0.00 (645.52) 0.00 (566.75) 0.0 pt
ROE 32.36 (223.15) (469.72) (41.44) (80.37) (117.42) (94.14) (48.95) (65.81) (68.81) (76.87) (101.2) pt
People
People Employees 8 7 11 28 44 56 67 8 5 5 — (5.1%)
Revenue/emp, $m 0.00 0.03 0.02 0.01 0.01 0.02 0.05 0.41 1.32 0.71 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2025 · fundamentals updated 25 Oct 2026

MARKER THERAPEUTICS, INC. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
VAXX Vaxxinity, Inc. $15.5M — (loss-making) — (loss-making) −100.23% (below 0%: shrinking) n/m +17.00% (above 0%: growing) 0.00% 0.00% Compare
ABOS Acumen Pharmaceuticals, Inc. $15.5M — (loss-making) — — n/m +12.58% (above 0%: growing) 0.00% 0.00% Compare
CTXR Citius Pharmaceuticals, Inc. $15.3M — (loss-making) — — n/m −60.50% (below 0%: shrinking) 67.07% (785.39%) Compare
PLUR Pluri Inc. $15.0M — (loss-making) — (loss-making) −15.83% (below 0%: shrinking) n/m +25.03% (above 0%: growing) 58.51% (1,655.52%) Compare
NEUP Neuphoria Therapeutics Inc. $15.0M — (loss-making) — (loss-making) −107.32% (below 0%: shrinking) n/m +133.86% (above 0%: growing) 100.00% 0.00% Compare
MRKR MARKER THERAPEUTICS, INC. $14.9M — (loss-making) — (loss-making) −51.00% (below 0%: shrinking) n/m −97.84% (below 0%: shrinking) 209.68% 0.00%
KYNB Kyntra Bio Inc $14.8M 0.1× — (loss-making) −209.35% (below 0%: shrinking) n/m −131.50% (below 0%: shrinking) 100.14% 1,192.27% Compare
ATYR aTyr Pharma, Inc. $14.8M — (loss-making) — (loss-making) −90.75% (below 0%: shrinking) n/m +32.22% (above 0%: growing) 100.00% 0.00% Compare
ADAPY Adaptimmune Therapeutics PLC $14.6M — (loss-making) — (loss-making) −89.33% (below 0%: shrinking) n/m −174.72% (below 0%: shrinking) 81.71% (221.45%) Compare
Median of peers $15.0M — — −95.49% — +14.79% 74.39% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 March 2026

Ownership

Directors and executive officers, together 5.70%
New Enterprise Associates 21.80%
Blue Owl Capital Holdings LP 16.20%
Alyeska Fund GP, LLC 10.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

MARKER THERAPEUTICS, INC. (MRKR) Latest News

19 Oct

Impact 4 · · GlobeNewswire

16 Oct

Impact 3 · · Zacks

22 Sep

Impact 4 ·

18 Mar

Impact 3 · · Zacks
Impact 3 · · GlobeNewswire

10 Feb

Impact 4 · · Simply Wall St.

5 Feb

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

3 Feb

Impact 4 · · Simply Wall St.
Impact 4 ·

2 Feb

Impact 4 · · Simply Wall St.
Impact 3 · · Simply Wall St.

30 Jan

Impact 3 · · Simply Wall St.

26 Jan

Impact 4 · · GlobeNewswire
Impact 4 ·

23 Jan

Impact 3 · · Simply Wall St.

22 Jan

Impact 4 · · Simply Wall St.

21 Jan

Impact 4 · · Zacks
Impact 3 · · Simply Wall St.
Impact 3 · · Simply Wall St.

20 Jan

Impact 3 · · Simply Wall St.

15 Jan

Impact 4 · · Simply Wall St.

13 Jan

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

9 Jan

Impact 4 · · Simply Wall St.

7 Jan

Impact 3 · · Zacks
Impact 3 · · Zacks

5 Jan

Impact 4 · · GlobeNewswire
Impact 4 · · Simply Wall St.

2 Jan

Impact 4 · · Simply Wall St.
stockrow.com/MRKR · Data as of Oct 25, 2026 · For information only; not investment advice. · © 2026 stockrow.com